A vaccine targeted at CETP alleviates high fat and high cholesterol diet-induced atherosclerosis and non-alcoholic steatohepatitis in rabbit

PLoS ONE

Volumn 9, Issue 12, 2014, Pages

  Liaw, Yi Wei ^a,e   Lin, Chi Yu ^c,e   Lai, Yu Sheng ^b   Yang, Tzu Chung ^b   Wang, Chau Jong ^d   Whang Peng, Jacqueline ^e   Liu, Leroy F ^e,f   Lin, Chia Po ^g   Nieh, Shin ^h   Lu, Shao Chun ^b   Hwang, Jaulang ^a,e  

^a NATIONAL YANG MING UNIVERSITY   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^c NATIONAL DEFENSE MEDICAL CENTER   (Taiwan)

^d CHUNG SHAN MEDICAL UNIVERSITY   (Taiwan)

^e TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^f RUTGERS ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^g Ministry of Health and Welfare   (Taiwan)

^h TRI SERVICE GENERAL HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN A1; CHOLESTEROL; CHOLESTEROL ESTER TRANSFER PROTEIN; CHOLESTEROL ESTER TRANSFER PROTEIN ANTIBODY; FC CHOLESTEROL ESTER TRANSFER PROTEIN 6 VACCINE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; OXIDIZED LOW DENSITY LIPOPROTEIN; PROTEIN ANTIBODY; UNCLASSIFIED DRUG; VACCINE; ANTIBODY; HYBRID PROTEIN; IMMUNOGLOBULIN FC FRAGMENT; LOW DENSITY LIPOPROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY PRODUCTION; AORTIC INFLAMMATION; ARTICLE; ATHEROSCLEROSIS; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL DIET; CONTROLLED STUDY; DRUG EFFICACY; ENZYME ACTIVITY; FEMALE; HEPATITIS; IMMUNIZATION; IMMUNOGENICITY; INFLAMMATION; LIPID DIET; LIPID STORAGE; LIPOPROTEIN BLOOD LEVEL; LIVER FIBROSIS; MACROPHAGE MIGRATION; NONALCOHOLIC FATTY LIVER; NONHUMAN; PROTEIN BLOOD LEVEL; ADVERSE EFFECTS; ANIMAL; BLOOD; DISEASE MODEL; FIBROSIS; GENE EXPRESSION; GENETICS; HUMAN; IMMUNOLOGY; METABOLISM; NON-ALCOHOLIC FATTY LIVER DISEASE; PATHOLOGY; RABBIT;

ORYCTOLAGUS CUNICULUS;

ANIMALS; ANTIBODIES; APOLIPOPROTEIN A-I; ATHEROSCLEROSIS; CHOLESTEROL; CHOLESTEROL ESTER TRANSFER PROTEINS; DIET, HIGH-FAT; DISEASE MODELS, ANIMAL; FEMALE; FIBROSIS; GENE EXPRESSION; HUMANS; IMMUNOGLOBULIN FC FRAGMENTS; LIPOPROTEINS, LDL; NON-ALCOHOLIC FATTY LIVER DISEASE; RABBITS; RECOMBINANT FUSION PROTEINS; VACCINES;

EID: 84915747326     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0111529     Document Type: Article

References (45)

1. Glass CK, Witztum JL (2001) Atherosclerosis. the road ahead. Cell 104: 503-516.
2. Rader DJ (2006) Molecular regulation of HDL metabolism and function: implications for novel therapies. J Clin Invest 116: 3090-3100.
3. Neuschwander-Tetri BA, Clark JM, Bass NM, Van Natta ML, Unalp-Arida A, et al. (2010) Clinical, laboratory and histological associations in adults with nonalcoholic fatty liver disease. Hepatology 52: 913-924.
4. Lucero D, Zago V, Lopez GI, Graffigna M, Lopez GH, et al. (2011) Does non-alcoholic fatty liver impair alterations of plasma lipoproteins and associated factors in metabolic syndrome? Clin Chim Acta 412: 587-592.
5. Musunuru K (2010) Atherogenic dyslipidemia: cardiovascular risk and dietary intervention. Lipids 45: 907-914.
6. Bieghs V, van Gorp PJ, Walenbergh SM, Gijbels MJ, Verheyen F, et al. (2012) Specific immunization strategies against oxidized low-density lipoprotein: a novel way to reduce nonalcoholic steatohepatitis in mice. Hepatology 56: 894-903.
7. Bieghs V, Wouters K, van Gorp PJ, Gijbels MJ, de Winther MP, et al. (2010) Role of scavenger receptor A and CD36 in diet-induced nonalcoholic steatohepatitis in hyperlipidemic mice. Gastroenterology 138: 2477-2486, , 2486 e2471-2473.
8. Targher G, Day CP, Bonora E (2010) Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. N Engl J Med 363: 1341-1350.
9. Assmann G, Schulte H, von Eckardstein A, Huang Y (1996) High-density lipoprotein cholesterol as a predictor of coronary heart disease risk. The PROCAM experience and pathophysiological implications for reverse cholesterol transport. Atherosclerosis 124 Suppl: S11-20.
10. Inazu A, Brown ML, Hesler CB, Agellon LB, Koizumi J, et al. (1990) Increased high-density lipoprotein levels caused by a common cholesteryl-ester transfer protein gene mutation. N Engl J Med 323: 1234-1238.
11. Barter PJ, Rye KA (2012) Cholesteryl ester transfer protein inhibition as a strategy to reduce cardiovascular risk. J Lipid Res 53: 1755-1766.
12. Honey K (2007) Drug designed to raise HDL levels falls down. J Clin Invest 117: 282.
13. Rhainds D, Arsenault BJ, Brodeur MR, Tardif JC (2012) An update on the clinical development of dalcetrapib (RO4607381), a cholesteryl ester transfer protein modulator that increases HDL cholesterol levels. Future Cardiol 8: 513-531.
14. Rader DJ, deGoma EM (2014) Future of cholesteryl ester transfer protein inhibitors. Annu Rev Med 65: 385-403.
15. Davidson MH, Maki K, Umporowicz D, Wheeler A, Rittershaus C, et al. (2003) The safety and immunogenicity of a CETP vaccine in healthy adults. Atherosclerosis 169: 113-120.
16. Swanson JA, Hoppe AD (2004) The coordination of signaling during Fc receptor-mediated phagocytosis. J Leukoc Biol 76: 1093-1103.
17. Gosselin EJ, Wardwell K, Gosselin DR, Alter N, Fisher JL, et al. (1992) Enhanced antigen presentation using human Fc gamma receptor (monocyte/macrophage)-specific immunogens. J Immunol 149: 3477-3481.
18. Ota H, Takashima Y, Hayashi Y, Matsumoto Y (2006) A fusion protein of IgG fc and mouse-derived antigen on the surface of pseudorabies virus particles does not accelerate production of harmful autoreactive antibodies. J Vet Med Sci 68: 1179-1183.
19. Puffer EB, Pontrello JK, Hollenbeck JJ, Kink JA, Kiessling LL (2007) Activating B cell signaling with defined multivalent ligands. ACS Chem Biol 2: 252-262.
20. Hsu CT, Ting CY, Ting CJ, Chen TY, Lin CP, et al. (2000) Vaccination against gonadotropin-releasing hormone (GnRH) using toxin receptor-binding domain-conjugated GnRH repeats. Cancer Res 60: 3701-3705.
21. Tall AR (1986) Plasma lipid transfer proteins. J Lipid Res 27: 361-367.
22. Ogawa T, Fujii H, Yoshizato K, Kawada N (2010) A human-type nonalcoholic steatohepatitis model with advanced fibrosis in rabbits. Am J Pathol 177: 153-165.
23. Gaofu Q, Dan M, Jie W, Liao Z, Li Z, et al. (2004) Long-lasting specific antibodies against CETP induced by subcutaneous and mucosal administration of a 26-amino acid CETP epitope carried by heat shock protein 65 kDa in the absence of adjuvants. Vaccine 22: 3187-3194.
24. Chang PY, Lu SC, Su TC, Chou SF, Huang WH, et al. (2004) Lipoprotein-X reduces LDL atherogenicity in primary biliary cirrhosis by preventing LDL oxidation. J Lipid Res 45: 2116-2122.
25. Chiang HL, Lin CY, Jan FD, Lin YS, Hsu CT, et al. (2012) A novel synthetic bipartite carrier protein for developing glycotope-based vaccines. Vaccine 30: 7573-7581.
26. Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, et al. (2005) Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 41: 1313-1321.
27. Navab M, Anantharamaiah GM, Fogelman AM (2005) The role of high-density lipoprotein in inflammation. Trends Cardiovasc Med 15: 158-161.
28. Smith JD (2010) Apolipoprotein A-I and its mimetics for the treatment of atherosclerosis. Curr Opin Investig Drugs 11: 989-996.
29. Chalasani N, Deeg MA, Crabb DW (2004) Systemic levels of lipid peroxidation and its metabolic and dietary correlates in patients with nonalcoholic steatohepatitis. Am J Gastroenterol 99: 1497-1502.
30. Libby P (2002) Inflammation in atherosclerosis. Nature 420: 868-874.
31. Buyssens N, Kockx MM, Herman AG, Lazou JM, Van den Berg K, et al. (1996) Centrolobular liver fibrosis in the hypercholesterolemic rabbit. Hepatology 24: 939-946.
32. Rittershaus CW, Miller DP, Thomas LJ, Picard MD, Honan CM, et al. (2000) Vaccine-induced antibodies inhibit CETP activity in vivo and reduce aortic lesions in a rabbit model of atherosclerosis. Arterioscler Thromb Vasc Biol 20: 2106-2112.
33. Bieghs V, Rensen PC, Hofker MH, Shiri-Sverdlov R (2012) NASH and atherosclerosis are two aspects of a shared disease: central role for macrophages. Atherosclerosis 220: 287-293.
34. Brea A, Mosquera D, Martin E, Arizti A, Cordero JL, et al. (2005) Nonalcoholic fatty liver disease is associated with carotid atherosclerosis: a case-control study. Arterioscler Thromb Vasc Biol 25: 1045-1050.
35. Cheng AM, Handa P, Tateya S, Schwartz J, Tang C, et al. (2012) Apolipoprotein A-I attenuates palmitate-mediated NF-kappaB activation by reducing Toll-like receptor-4 recruitment into lipid rafts. PLoS One 7: e33917.
36. Patel S, Di Bartolo BA, Nakhla S, Heather AK, Mitchell TW, et al. (2010) Anti-inflammatory effects of apolipoprotein A-I in the rabbit. Atherosclerosis 212: 392-397.
37. Nicholls SJ, Tuzcu EM, Brennan DM, Tardif JC, Nissen SE (2008) Cholesteryl ester transfer protein inhibition, high-density lipoprotein raising, and progression of coronary atherosclerosis: insights from ILLUSTRATE (Investigation of Lipid Level Management Using Coronary Ultrasound to Assess Reduction of Atherosclerosis by CETP Inhibition and HDL Elevation). Circulation 118: 2506-2514.
38. Cannon CP, Shah S, Dansky HM, Davidson M, Brinton EA, et al. (2010) Safety of anacetrapib in patients with or at high risk for coronary heart disease. N Engl J Med 363: 2406-2415.
39. Brousseau ME, Millar JS, Diffenderfer MR, Nartsupha C, Asztalos BF, et al. (2009) Effects of cholesteryl ester transfer protein inhibition on apolipoprotein A-II-containing HDL subspecies and apolipoprotein A-II metabolism. J Lipid Res 50: 1456-1462.
40. Brousseau ME, Diffenderfer MR, Millar JS, Nartsupha C, Asztalos BF, et al. (2005) Effects of cholesteryl ester transfer protein inhibition on high-density lipoprotein subspecies, apolipoprotein A-I metabolism, and fecal sterol excretion. Arterioscler Thromb Vasc Biol 25: 1057-1064.
41. Clark RW, Ruggeri RB, Cunningham D, Bamberger MJ (2006) Description of the torcetrapib series of cholesteryl ester transfer protein inhibitors, including mechanism of action. J Lipid Res 47: 537-552.
42. Zhang L, Yan F, Zhang S, Lei D, Charles MA, et al. (2012) Structural basis of transfer between lipoproteins by cholesteryl ester transfer protein. Nat Chem Biol 8: 342-349.
43. Blake WL, Ulrich RG, Marotti KR, Melchior GW (1994) The development of fatty liver is accelerated in transgenic mice expressing cynomolgus monkey cholesteryl ester transfer protein. Biochem Biophys Res Commun 205: 1257-1263.
44. Bhatia LS, Curzen NP, Calder PC, Byrne CD (2012) Non-alcoholic fatty liver disease: a new and important cardiovascular risk factor? Eur Heart J 33: 1190-1200.
45. Farrell GC, Larter CZ (2006) Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology 43: S99-S112.